Russell V Luepker1, Niki C Oldenburg2, Jeffrey R Misialek3, Jeremy R Van't Hof2, John R Finnegan4, Milton Eder5, Sue Duval2. 1. Division of Epidemiology & Community Health, School of Public Health, University of Minnesota, Minneapolis, Minnesota; Cardiovascular Division & Lillehei Heart Institute, University of Minnesota Medical School, Minneapolis, Minnesota. Electronic address: luepk001@umn.edu. 2. Cardiovascular Division & Lillehei Heart Institute, University of Minnesota Medical School, Minneapolis, Minnesota. 3. Division of Epidemiology & Community Health, School of Public Health, University of Minnesota, Minneapolis, Minnesota; Cardiovascular Division & Lillehei Heart Institute, University of Minnesota Medical School, Minneapolis, Minnesota. 4. Division of Epidemiology & Community Health, School of Public Health, University of Minnesota, Minneapolis, Minnesota. 5. Department of Family Medicine and Community Health, University of Minnesota Medical School, Minneapolis, Minnesota.
Abstract
INTRODUCTION: Daily aspirin use for primary cardiovascular disease prevention is common among adults. Numerous clinical trials observe reduced cardiovascular disease with regular low-dose aspirin. The U.S. Preventive Services Task Force in 2016 published guidelines for aspirin use, but controversy exists about the side effects, and overuse or underuse may be common despite the guidelines. Using the Task Force recommendations, this paper describes the prevalence of appropriate aspirin use and physician advice in a population sample. METHODS: A random sample of men and women (aged 50-69 years) living in the Upper Midwest in 2017-2018 were surveyed, collecting demographic data, health history, and aspirin use. Appropriate primary prevention with aspirin was defined as having ≥10% cardiovascular disease risk (hypertension, hyperlipidemia, diabetes, smoking) with daily or every other day aspirin use. Those with prevalent cardiovascular disease were labeled as secondary prevention. RESULTS: A total of 1,352 adults were surveyed (697 women, 655 men). The criteria for secondary prevention were fulfilled in 188 participants, and these were eliminated from the analysis. In the remaining group, aspirin was indicated in 32.9% (383 of 1,164). Among those, 46.0% (176 of 383) were appropriate users, and 54.0% (207 of 383) were nonusers despite indications. Overuse, where aspirin is not indicated, was common at 26.9% (210 of 781). Discussion with a physician, although reported in 29% of subjects, was associated with some improvement in the appropriate use but also with overuse and underuse. CONCLUSIONS: Aspirin use for primary cardiovascular disease prevention is common. However, many adults are medicating without indication (overuse) or are not using aspirin despite guidelines (underuse).
INTRODUCTION: Daily aspirin use for primary cardiovascular disease prevention is common among adults. Numerous clinical trials observe reduced cardiovascular disease with regular low-dose aspirin. The U.S. Preventive Services Task Force in 2016 published guidelines for aspirin use, but controversy exists about the side effects, and overuse or underuse may be common despite the guidelines. Using the Task Force recommendations, this paper describes the prevalence of appropriate aspirin use and physician advice in a population sample. METHODS: A random sample of men and women (aged 50-69 years) living in the Upper Midwest in 2017-2018 were surveyed, collecting demographic data, health history, and aspirin use. Appropriate primary prevention with aspirin was defined as having ≥10% cardiovascular disease risk (hypertension, hyperlipidemia, diabetes, smoking) with daily or every other day aspirin use. Those with prevalent cardiovascular disease were labeled as secondary prevention. RESULTS: A total of 1,352 adults were surveyed (697 women, 655 men). The criteria for secondary prevention were fulfilled in 188 participants, and these were eliminated from the analysis. In the remaining group, aspirin was indicated in 32.9% (383 of 1,164). Among those, 46.0% (176 of 383) were appropriate users, and 54.0% (207 of 383) were nonusers despite indications. Overuse, where aspirin is not indicated, was common at 26.9% (210 of 781). Discussion with a physician, although reported in 29% of subjects, was associated with some improvement in the appropriate use but also with overuse and underuse. CONCLUSIONS: Aspirin use for primary cardiovascular disease prevention is common. However, many adults are medicating without indication (overuse) or are not using aspirin despite guidelines (underuse).
Authors: D K Arnett; J M Sprafka; P G McGovern; D R Jacobs; E Shahar; M McCarty; R V Luepker Journal: Am J Public Health Date: 1998-08 Impact factor: 9.308
Authors: Hesham K Abdelaziz; Marwan Saad; Naga Venkata K Pothineni; Michael Megaly; Rahul Potluri; Mohammed Saleh; David Lai Chin Kon; David H Roberts; Deepak L Bhatt; Herbert D Aronow; J Dawn Abbott; Jawahar L Mehta Journal: J Am Coll Cardiol Date: 2019-06-18 Impact factor: 24.094
Authors: Craig D Williams; Andrew T Chan; Miriam R Elman; Alyson H Kristensen; W Fred Miser; Michael P Pignone; Randall S Stafford; Jessina C McGregor Journal: Am J Prev Med Date: 2015-05 Impact factor: 5.043
Authors: Louise Bowman; Marion Mafham; Karl Wallendszus; Will Stevens; Georgina Buck; Jill Barton; Kevin Murphy; Theingi Aung; Richard Haynes; Jolyon Cox; Aleksandra Murawska; Allen Young; Michael Lay; Fang Chen; Emily Sammons; Emma Waters; Amanda Adler; Jonathan Bodansky; Andrew Farmer; Roger McPherson; Andrew Neil; David Simpson; Richard Peto; Colin Baigent; Rory Collins; Sarah Parish; Jane Armitage Journal: N Engl J Med Date: 2018-08-26 Impact factor: 91.245
Authors: Sigrun Halvorsen; Felicita Andreotti; Jurriën M ten Berg; Marco Cattaneo; Sergio Coccheri; Roberto Marchioli; João Morais; Freek W A Verheugt; Raffaele De Caterina Journal: J Am Coll Cardiol Date: 2014-07-22 Impact factor: 24.094